Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • STING agonist-1: High-Purity Small Molecule for STING Pat...

    2026-02-24

    STING agonist-1: High-Purity Small Molecule for STING Pathway Activation

    Executive Summary: STING agonist-1, supplied by APExBIO, is a small molecule activator of the STING pathway with ≥98% purity, validated by HPLC and NMR (product page). It induces type I interferons and cytokines, facilitating innate immunity studies (Zheng et al. 2025). The compound enables reliable dissection of non-canonical NF-κB signaling and B cell activation in cancer and inflammation models. Its DMSO solubility and stringent storage/shipping controls ensure experimental reproducibility. STING agonist-1 supports advanced research into tertiary lymphoid structure formation and biomarkers for cancer immunotherapy (IFN-Y.com).

    Biological Rationale

    The STING (Stimulator of Interferon Genes) pathway is central to the innate immune response. It detects cytosolic DNA, leading to the production of type I interferons (IFNs) and pro-inflammatory cytokines. These cytokines recruit and activate immune cells, such as dendritic cells and B cells, facilitating both innate and adaptive immunity (Zheng et al. 2025). In oncology, STING pathway activation is linked to improved antitumor immunity, including the formation of tertiary lymphoid structures (TLS) and enhanced B cell activation. TLS presence correlates with favorable survival in esophageal squamous cell carcinoma (ESCC) and other malignancies. The upregulation of IRF4, a transcription factor, is a hallmark of STING-driven B cell activation. STING agonist-1, a synthetic small molecule, mimics endogenous cyclic dinucleotides to trigger this pathway, enabling precise immunological studies.

    Mechanism of Action of STING agonist-1

    STING agonist-1, chemically designated as (Z)-4-(2-chloro-6-fluorobenzyl)-N-(furan-2-ylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carbimidic acid, directly binds and activates the STING adaptor protein. Upon binding, STING translocates from the endoplasmic reticulum to the Golgi apparatus, where it recruits TANK-binding kinase 1 (TBK1). TBK1 phosphorylates interferon regulatory factor 3 (IRF3), which then translocates to the nucleus to promote transcription of type I IFN genes. In B cells, STING activation also triggers non-canonical NF-κB signaling via TRAF2, with IRF4 upregulation as a downstream marker (Zheng et al. 2025). STING agonist-1’s small molecule format allows cell-permeable, reproducible pathway activation, distinct from larger, less stable cyclic dinucleotide agonists. The compound is soluble in DMSO and stable at -20°C, ensuring experimental consistency (APExBIO).

    Evidence & Benchmarks

    • STING agonist-1 induces robust type I interferon (IFN-β) transcription in cell line models at concentrations as low as 0.5–2 μM in DMSO (Zheng et al. 2025).
    • Activation of the STING pathway in B cells leads to upregulation of IRF4 and promotes TLS formation in tumor microenvironments (Zheng et al. 2025).
    • The product achieves ≥98% purity, confirmed by HPLC and NMR analyses under standard conditions (room temperature, neutral pH) (APExBIO).
    • STING agonist-1 exhibits high solubility in DMSO up to 10 mM stock concentrations, facilitating accurate dosing (APExBIO).
    • Competitive binding of STING and CD40 with TRAF2 is required for IRF4-mediated B cell activation, as shown in in vitro ESCC models (Zheng et al. 2025).

    This article expands on previous coverage by detailing non-canonical NF-κB signaling benchmarks and the competitive TRAF2 binding mechanism, not emphasized in prior summaries. For additional Q&A and troubleshooting, see Optimizing Innate Immunity Assays, which focuses on application nuances; this article instead foregrounds atomic, testable claims and mechanism-of-action insights.

    Applications, Limits & Misconceptions

    STING agonist-1 is validated for use in immunology, inflammation, and cancer biology research. Its primary applications include:

    • Dissection of the STING pathway in cell-based and animal models.
    • Induction of type I interferons and cytokines for innate immunity assays.
    • Investigation of B cell activation and TLS formation in tumor microenvironments.
    • Development and benchmarking of immunomodulatory therapies and biomarkers.

    However, it is not intended for:

    • Long-term solution storage; activity decays rapidly in solution even at -20°C.
    • Direct clinical or in vivo therapeutic use; it is strictly a research reagent.
    • Activation of pathways unrelated to STING, such as TLR or RIG-I, without off-target validation.

    Common Pitfalls or Misconceptions

    • Assuming stability in aqueous buffers: STING agonist-1 is DMSO-soluble and may degrade in water.
    • Expecting clinical efficacy: The product is for research use only, not a drug.
    • Confusing B cell activation with T cell responses: The compound primarily modulates B cells and innate immunity (Zheng et al. 2025).
    • Using expired or improperly stored material: Store at -20°C, avoid multiple freeze-thaw cycles.
    • Assuming cross-activation of all species' STING orthologs: Species-specific differences exist and should be validated.

    For an in-depth mechanistic perspective, this article explores B cell-driven immunity via non-canonical NF-κB signaling, while the current review contextualizes these findings specifically for STING agonist-1 reagent selection and use.

    Workflow Integration & Parameters

    STING agonist-1 is supplied as a solid, shipped on blue ice to maintain stability. For experimental use:

    • Prepare fresh DMSO stock solutions at 10 mM; avoid water as the primary solvent.
    • Aliquot and store at -20°C; minimize freeze-thaw cycles.
    • Use promptly after dilution; do not store solutions for more than 24 hours.
    • Apply concentrations between 0.5–10 μM for cell-based assays, titrating as needed.
    • Verify purity by HPLC/NMR if extended storage is anticipated.

    Detailed, stepwise protocols and troubleshooting are available in this guide; unlike the present article, that resource provides protocol-level walkthroughs, while this review prioritizes verifiable claims and mechanism-of-action summaries.

    Conclusion & Outlook

    STING agonist-1, as supplied by APExBIO, is a high-purity, DMSO-soluble small molecule validated for research on STING pathway activation, innate immunity, and B cell-mediated antitumor responses. Its robust benchmarking, mechanistic specificity, and stringent quality controls make it a reference immunology research reagent. Ongoing studies continue to refine best practices for its use in dissecting tertiary lymphoid structure biology and developing new biomarkers for cancer immunotherapy. For ordering and technical documentation, visit the official STING agonist-1 product page.